Skip to main content
. Author manuscript; available in PMC: 2017 Jun 16.
Published in final edited form as: Neuroepidemiology. 2016 Jan 28;46(2):128–136. doi: 10.1159/000443794

Table 4.

Logistic regression analysis of factors predicting cancers in movement disorders

Unadjusted model Liberal adjusted model1 Conservative adjusted model4



diagnosis OR 95% CI significance diagnosis OR 95% CI significance diagnosis OR 95% CI significance
Any type of cancer
PD 1.69 0.99–2.86 0.05 PD 1.97 1.049–3.71 0.04 PD 1.69 0.99–2.86 0.05
ET 1.09 0.66–1.81 0.73 ET 1.08 0.62–1.89 0.79 ET 1.09 0.66–1.81 0.73
Dystonia 1.20 0.62–2.32 0.59 Dystonia 1.16 0.58–2.32 0.67 Dystonia 1.20 0.62–2.32 0.59
Controls 1.00 Controls 1.00 Controls 1.00

Unadjusted model Liberal adjusted model2 Conservative adjusted model4

Melanoma
PD 9.84 2.20–44.09 0.003 PD 7.09 1.52–33.0 0.01 PD 9.84 2.20–44.09 0.003
ET 3.73 0.78–17.89 0.10 ET 4.10 0.83–20.2 0.08 ET 3.73 0.78–17.89 0.10
Dystonia 4.88 0.87–27.50 0.07 Dystonia 5.27 0.90–30.93 0.06 Dystonia 4.88 0.87–27.50 0.07
Controls 1.00 Controls 1.00 Controls 1.00

Unadjusted model Liberal adjusted model3 Conservative adjusted model4

Integumentary cancers
PD 3.63 1.86–7.11 0.0002 PD 2.63 1.24–5.62 0.01 PD 3.63 1.86–7.11 0.0002
ET 1.75 0.88–3.47 0.10 ET 1.47 0.71–3.06 0.31 ET 1.75 0.88–3.47 0.10
Dystonia 2.54 1.13–5.74 0.03 Dystonia 2.21 0.90–5.45 0.07 Dystonia 2.54 1.13–5.74 0.03
Controls 1.00 Controls 1.00 Controls 1.00
1

Adjusted for number of prescription medications, age in years, Caucasian race and Cumulative Illness Rating Scale Score.

2

Adjusted for number of prescription medications.

3

Adjusted for number of prescription medications and years since last hospitalization.

4

The conservative model resembled the unadjusted model because there were no variables that met stringent criteria for inclusion in the model.

Liberal models included variables that were associated either with the cancer in question or the diagnosis in question.

Conservative models included variables that were associated both with the cancer in question and the diagnosis in question.